Skip to content

A randomised double blind controlled trial of nitazoxanide in intestinal polyparasitism in humans: a Brazilian study

A randomised double blind controlled trial of nitazoxanide of the treatment in intestinal polyparasitism in humans

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ISRCTN
Registry ID
ISRCTN74820169
Enrollment
60
Registered
2008-09-18
Start date
2008-07-01
Completion date
Unknown
Last updated
2015-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Intestinal polyparasitism Infections and Infestations Unspecified parasitic disease

Interventions

1. Nitazoxanide = 15 mg/kg/day every 12 hours for children, 500 mg tablet every 12 hours for adults, during three days 2. Secnidazole = 30 mg/kg/day for children and 2 g for adults in one dose 3. Albe

Sponsors

Federal University of Juiz de Fora (Brazil)
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. Participants more than one year of age, either sex 2. Positive for one or more species of intestinal parasites 3. Rural populations in the Zona da Mata of the State of Minas Gerais (Brazil) 4. Taken care of by the Unified National Health System (SUS)

Exclusion criteria

Exclusion criteria: 1. Intestinal obstruction for intestinal parasitisms 2. Pregnant 3. Patients with liver or renal insufficiency 4. Alterations in biliary treatment 5. Patient is using warfarin, aspirin, phenytoin, carbamazepine or valproic acid

Design outcomes

Primary

MeasureTime frame
1. Cure (non-infected) defined as an absence of any species of parasite in the examination of excrements 2. Cure absence (infected) defined as maintenance of the pre-existing parasite These outcomes will be measured in July and September 2008.

Secondary

MeasureTime frame
Prevalence of adverse effects. These outcomes will be measured in July and September 2008.

Countries

Brazil

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026